Palatin Technologies

403 articles about Palatin Technologies

• Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

  4/8/2024

  Palatin Technologies, Inc. announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease at the American Society of Cataract and Refractive Surgery.

• 

  Palatin’s Dry Eye Drug Candidate Flops in Phase III Trial

  3/1/2024

  Palatin Technologies’ melanocortin agonist PL9643 came up short in a late-stage study evaluating its safety and efficacy.

• Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

  2/28/2024

  Palatin Technologies, Inc.  today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

• Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

  2/15/2024

  Palatin Technologies, Inc. announced financial results for its fiscal second quarter ended December 31, 2023.

• Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

  2/9/2024

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

• Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

  2/5/2024

  Palatin Technologies, Inc. today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

• Palatin Announces Closing of $10 Million Registered Direct Offering

  2/1/2024

  Palatin Technologies, Inc. announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock.

• Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

  1/8/2024

  Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, provided a corporate update, highlighted the Company's key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones.

• Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

  1/3/2024

  Cosette Pharmaceuticals Acquires Vyleesi ® (Bremelanotide Injection) from Palatin Technologies Inc.

• Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

  12/20/2023

  Palatin Technologies, Inc. today announced the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million.

• Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

  12/18/2023

  Palatin Technologies, Inc. announced it received a notice from the staff of NYSE American LLC approving Palatin's plan to come into compliance with the Exchange's continued listing standards under Section 1003 and of the NYSE American Company Guide.

• Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

  11/14/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update.

• Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

  11/9/2023

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.

• Palatin Announces Closing of $5 Million Registered Direct Offering

  10/24/2023

  Palatin Technologies, Inc. announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common stock, at a purchase price of $2.12 per share of common stock.

• Palatin Announces $5 Million Registered Direct Offering

  10/23/2023

  Palatin Technologies, Inc. today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an aggregate of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof).

• Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

  10/19/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal year 2024 first quarter ended September 30, 2023 results, for Vyleesi® product revenue.

• Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

  10/18/2023

  Palatin Technologies, Inc. (NYSE American: PTN) today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024. 

• Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

  10/16/2023

  Palatin Technologies, Inc. (NYSE American: PTN) today announced the presentation of a poster entitled Cellular and Molecular Impact of the Melanocortin Receptor Agonist PL8177 in DSS Induced Colitis in Rats  at  the United European Gastroenterology Week (UEG) being held October 14-17 2023 in Copenhagen, Denmark.

• Palatin Receives Notice of Non-Compliance from NYSE American

  10/13/2023

  Palatin Technologies, Inc. announced it received a notice from the staff of NYSE American LLC that Palatin was not in compliance with the Exchange's continued listing standards under Section 1003 and of the NYSE American Company Guide.

• Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

  9/28/2023

  Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2023.